Leone, José Pablo
Lin, Nancy U.
Article History
First Online: 8 April 2019
Change Date: 17 May 2019
Change Type: Correction
Change Details: The original version of this article, which published in <i>Current Oncology Reports</i>, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer.
Compliance with Ethical Standards
:
: José Pablo Leone has received research funds paid to his institution (University of Iowa) from Merck and has also received research funds from Kazia Therapeutics and Eli Lilly.Nancy U. Lin has received funding for clinical trials from Genentech, Seattle Genetics, Novartis, and Pfizer, and has received compensation from Puma and Daiichi for service as a consultant.
: This article does not contain any studies with human or animal subjects performed by any of the authors.